Conceived and designed the experiments: JJS JB FM PC. Performed the experiments: JJS JB. Analyzed the data: JJS JB FM AB PC. Contributed reagents/materials/analysis tools: AB. Wrote the paper: JJS JB FM AB PC.
The authors have declared that no competing interests exist.
The majority of chemotherapy drugs are dosed based on body surface area (BSA). No standard BSA values for patients being treated in the United Kingdom are available on which to base dose and cost calculations. We therefore retrospectively assessed the BSA of patients receiving chemotherapy treatment at three oncology centres in the UK between 1st January 2005 and 31st December 2005.
A total of 3613 patients receiving chemotherapy for head and neck, ovarian, lung, upper GI/pancreas, breast or colorectal cancers were included. The overall mean BSA was 1.79 m2 (95% CI 1.78–1.80) with a mean BSA for men of 1.91 m2 (1.90–1.92) and 1.71 m2 (1.70–1.72) for women. Results were consistent across the three centres. No significant differences were noted between treatment in the adjuvant or palliative setting in patients with breast or colorectal cancer. However, statistically significant, albeit small, differences were detected between some tumour groups.
In view of the consistency of results between three geographically distinct UK cancer centres, we believe the results of this study may be generalised and used in future costings and budgeting for new chemotherapy agents in the UK.
Body surface area (BSA), despite well-documented limitations, remains the most frequently used measure for calculating the dose of cytotoxic drugs in chemotherapy regimens
The most widely used formula for BSA calculation is that devised by Du Bois and Du Bois in 1916. Plaster of Paris moulds of nine subjects were cut into small pieces in an attempt to measure the two-dimensional surface area of the skin. Each individual's body/skin surface area was then calculated and Du Bois and Du Bois determined that BSA was related to height and weight by the formula: weight (kg) 0.425×height (cm) 0.725×0.007184
Drug dosage is usually determined by multiplying the patient's BSA by a constant that has been derived for each drug in phase 1 and 2 studies. Despite calls for BSA dosing to be replaced with dosing based on pharmacokinetics or pharmacodynamics, these new methods are yet to be agreed upon
With the development of new, usually costly chemotherapy and immunotherapy drugs, the commissioners and providers of cancer care as well as the National Health Service (NHS) as a whole, need to estimate how much a particular therapy will on average cost per year. Such estimates rely in part on an accurate assessment of body surface area. Although a mean BSA of 1.73 m2 has been quoted in previous work
More recent studies performed outside the UK provide some guidance. An Australian study
The lack of a standard BSA value on which to base these dose and cost calculations is reflected in the varying values used by the National Institute for Health and Clinical Excellence (NICE) in the appraisal of new agents. For instance, in recent guidance on the administration of cetuximab and bevacizumab to patients with metastatic colorectal cancer a mean BSA of 1.75 m2 was used
Dose banding, whereby prescribed chemotherapy doses are rounded up or down to pre-determined standard doses, is a common practice including in the three centres studied. In some malignancies, this reduces waste, treatment delays and minimises errors in making up unusual volumes of chemotherapy agent
This study was designed to establish the mean BSA of patients receiving chemotherapy in the UK and whether there are statistically significant differences in the BSA values for:
Typeface="12";patients in different parts of the country
Typeface="12";men and women
Typeface="12";patients with different tumour types
Typeface="12";patients receiving adjuvant chemotherapy and those receiving palliative or second line treatment.
With this information, more accurate estimates can be made of the average dose of an agent and the likely consequent cost to a service of expensive drugs.
The study did not require patient consent or approval by an ethics committee, as no intervention was involved, data were anonymised and no patient identifying information was included.
A retrospective study was performed assessing patients receiving chemotherapy treatment in three cancer centres in different areas of England and Wales–the Clatterbridge Centre for Oncology in Merseyside, Velindre Cancer Centre in Cardiff and the Dorset Cancer Centre in Poole.
In each of these centres, data were collected on patients who started a chemotherapy regimen between 1st January 2005 and 31st December 2005. Patients receiving chemotherapy for the following cancers were included: head and neck, ovarian, lung, upper GI/pancreas, breast and colorectal. All intravenous and oral chemotherapy regimens were included except single agent carboplatin because the dose calculation for this drug is independent of BSA. Immunotherapies, intrathecal and intrapleural chemotherapies were also excluded. No minimum age was applied.
In Poole and Cardiff, where records of all chemotherapy prescriptions are kept electronically, it was possible to obtain all the relevant data by exporting patients' details from computerised chemotherapy programmes (Clinichemo and ChemoCare). A proportion of the lung cancer patients in Cardiff received their chemotherapy at Llandough Hospital and data about height, weight and BSA were obtained from the local tumour-specific database.
In Clatterbridge, chemotherapy prescriptions are not recorded electronically and so only demographic data could be obtained electronically from the MAXIMS database. Height, weight and BSA were obtained from the original chemotherapy scripts, which are filed with the patients' clinical records.
The age, sex, height and weight for each patient were recorded. The BSA on their chemotherapy prescription was also noted. If a patient started more than one chemotherapy regimen during the 12 month period, the data were collected for each regimen because their weight and hence BSA might have changed. Treatment intent (i.e. neo/adjuvant or palliative) was also recorded for all patients with breast or colorectal cancer. Only a small percentage of patients received neoadjuvant chemotherapy, and these cases were included in the adjuvant group for analysis.
The above data were entered into Excel spreadsheets. We recalculated the BSA for each patient using the Dubois and Dubois method (BSA (m2) = Wt (kg) 0.425×Ht (cm)0.725×0.007184) and this value was used for further calculations. This was done to verify the accuracy of the original calculation and to remove any dose capping.
Statistical analyses were performed using SPSS version 15. All significance testing employed an independent sample Student's t-test, and was 2- tailed.
A total of 4318 patients were identified as meeting the eligibility criteria. A full data set was obtained for 3613 patients (84%), and over 80% of patients from each centre were included (
Only cases in which a full dataset could be obtained were included in the study. This was possible for over 80% of patients in all 3 centres, with only a relatively small number excluded, mainly due to misfiling or loss of chemotherapy scripts.
Velindre | Clatterbridge | Dorset | Combined | |
Number eligible | 1310 | 2405 | 603 | 4318 |
Included (%) | 1077 (82) | 2035 (85) | 501 (83) | 3613 (84) |
Median Age | 61 | 60 | 65 | 61 |
Male (%) | 427 (39.6) | 843 (41.4) | 201 (40.1) | 1471 (40.7) |
Female (%) | 650 (60.4) | 1192 (58.6) | 300 (59.9) | 2142 (59.3) |
The overall mean BSA for the patient population was 1.79 m2 (95% CI 1.78, 1.80). For both sexes, the BSA distribution was approximately normal as shown in
As illustrated, the distribution approximates normal in both sexes.
The difference in mean BSA between male and female patients was statistically significant (p<0.0005), and apparent in all sub-groups, as shown in
The BSA was negatively correlated with age in both genders as shown in the scatterplots above. The Pearson correlation coefficient was −0.124 and −0.157 respectively and both results were statistically significant (p<0.0005).
Male | Female | ||
Adjuvant Breast | n | 4 | 685 |
Mean (CI) | 2.10 (1.59,2.61) | 1.75(1.74,1.77) | |
Palliative Breast | n | 4 | 282 |
Mean (CI) | 2.06 (1.85,2.28) | 1.74 (1.72,1.76) | |
Adjuvant Colon | n | 335 | 210 |
Mean (CI) | 1.92 (1.90,1.94) | 1.68 (1.65,1.70) | |
Palliative Colon | n | 291 | 151 |
Mean (CI) | 1.93 (1.91,1.96) | 1.68 (1.65,1.71) | |
Head and Neck | n | 117 | 38 |
Mean (CI) | 1.85 (1.81,1.88) | 1.65 (1.59,1.72) | |
Lung | n | 390 | 331 |
Mean (CI) | 1.89 (1.87,1.91) | 1.65 (1.64,1.67) | |
Ovarian | n | 0 | 321 |
Mean (CI) | - | 1.71 (1.69,1.73) | |
Upper GI | n | 330 | 124 |
Mean (CI) | 1.90 (1.88,1.92) | 1.65 (1.62,1.69) | |
Combined | n | 1471 | 2142 |
Mean (CI) | 1.91 (1.90, 1.91) | 1.71 (1.70, 1.72) |
Velindre | Clatterbridge | Dorset | Combined | ||
Adjuvant Breast | n | 207 | 430 | 52 | 689 |
Mean (CI) | 1.76 (1.73,1.78) | 1.76 (1.74,1.78) | 1.74 (1.69,1.78) | 1.76 (1.74,1.77) | |
Palliative Breast | n | 80 | 170 | 36 | 286 |
Mean (CI) | 1.74 (1.69,1.78) | 1.75 (1.72,1.77) | 1.73 (1.67,1.79) | 1.74 (1.72,1.76 | |
Adjuvant Colon | n | 158 | 308 | 79 | 545 |
Mean (CI) | 1.81 (1.78,1.84) | 1.84 (1.81,1.86) | 1.81 (1.76,1.86) | 1.83 (1.81,1.84) | |
Palliative Colon | n | 186 | 214 | 42 | 442 |
Mean (CI) | 1.83 (1.80,1.86) | 1.86 (1.82,1.89) | 1.86 (1.80,1.92) | 1.85 (1.83,1.87) | |
H & N | n | 43 | 67 | 45 | 155 |
Mean (CI) | 1.75 (1.68,1.82) | 1.83 (1.78,1.88) | 1.80 (1.75,1.86) | 1.80 (1.77,1.83) | |
Lung | n | 154 | 486 | 81 | 721 |
Mean (CI) | 1.77 (1.73,1.80) | 1.78 (1.76,1.80) | 1.84 (1.80,1.88) | 1.78 (1.77,1.80) | |
Ovarian | n | 107 | 114 | 100 | 321 |
Mean (CI) | 1.72 (1.69,1.75) | 1.71 (1.68,1.75) | 1.71 (1.67,1.75) | 1.71 (1.69,1.73) | |
Upper GI | n | 142 | 246 | 66 | 454 |
Mean (CI) | 1.81 (1.78,1.84) | 1.84 (1.82,1.87) | 1.84 (1.78,1.88) | 1.83 (1.81,1.85) | |
Combined | n | 1077 | 2035 | 501 | 3613 |
Mean (CI) | 1.78 (1.77–1.79) | 1.79 (1.79,1.80) | 1.79 (1.77,1.81) | 1.79 (1.78,1.80) |
A comparison was made between the BSA for patients receiving neoadjuvant or adjuvant chemotherapy and those receiving treatment in the palliative setting for breast and colorectal carcinoma. In both instances there were no statistically significant differences (p = 0.323 and p = 0.152 respectively).
On the other hand, differences between tumour sites are apparent. The mean BSA for women with breast cancer was significantly higher than those for women with colorectal, head and neck, lung, upper GI and ovarian cancer (p<0.0005, 0.001, <0.0005, <0.0005 and 0.002 respectively). However, no statistically significant differences were observed among the latter five groups.
In men, a higher mean BSA was observed in those with colorectal cancer compared to those with upper GI, lung or head and neck cancer (p = 0.019, 0.002 and <0.0005 respectively). Men with head and neck cancer also had a significantly lower BSA than those with either lung or upper GI cancer (p = 0.026 and 0.010 respectively).
Recent media coverage continues to highlight the problems of introducing new, costly cancer chemotherapy agents into the NHS. Regulatory bodies in several countries, including the UK, routinely consider evidence of cost-effectiveness when deciding on reimbursement of new therapeutic agents. Evaluation of cost effectiveness as carried out by the NICE technology appraisal process
The importance of using accurate data and appropriate calculation methods can be illustrated from experience in the UK, where NICE considered the merits of pemetrexed
However, the calculations employed a relatively low mean BSA, and did not take into consideration the effects of the distibution of BSA values in the population. The latter may have a significant effect on the final estimate of incremental cost, due mainly to effects on vial usage. Chemotherapy agents are frequently marketed in large vial sizes, leading to a stepwise rather than continuous increase in vials (and hence cost) with increasing BSA. Although vial sharing may help prevent wastage, this is only possible in relatively large centres for more common tumour types, and may be affected by the stability of the agent.
Using the BSA results for lung cancer patients in
In the absence of reliable estimates of BSA distribution in UK adult patients with cancer, cost-effectiveness evaluations have previously depended on the use of data derived from studies conducted in other countries (
Area | Average Body Surface area |
USA | 1.86 m2 (Baker et al) |
Not reported | 1.73 m2 (Ratain) |
Australia | 1.80 m2 (Dooley et al) |
UK | 1.79 m2 (Sacco et al) |
Unsurprisingly BSA varied with both sex and age. Men had a significantly higher BSA value than women (p<0.0005) and for both men and women the BSA declined with age (
This study was designed to allow calculation of the mean BSA for patients with different tumour types. The tumour sites selected reflect those patients commonly treated with chemotherapy (such as breast cancer). On the other hand prostate cancer, which is primarily treated with hormone therapy was not included. This is reflected in the higher proportion of female patients in this study, as breast cancer and prostate cancer are the most common cancers in men and women respectively. We specifically concentrated on larger groups to eliminate the bias from small numbers of patients treated with chemotherapy for other tumour sites. We feel that most of the tumour site groups are large enough to allow generalisation of results although we acknowledge that we had data on comparatively few (155) head and neck cancer patients. Because of this criterion, we have included two tumour sites, breast and ovary, for which the patients are almost all female, which accounts for the higher proportion of female patients in this study.
It is commonly assumed that patients receiving palliative chemotherapy have a lower BSA than those receiving treatment in the neoadjuvant or adjuvant setting, because the more advanced tumours might be associated with significant anorexia and weight loss. We analysed data from two tumour sites (breast and colorectal carcinoma) to investigate this hypothesis. In both cases, there was no statistically significant difference between the mean BSA results, even though palliative chemotherapy included second and third line regimens. This might be due to stringent patient selection for palliative chemotherapy making it less likely that patients with significant weight loss received chemotherapy.
However, small but statistically significant differences were observed between some tumour groups. In particular, women with ovarian cancer had a significantly lower BSA than those with breast cancer and patients with lung cancer had a significantly lower BSA than those with colon cancer. In both cases this is presumably related to the well known association of both ovarian and lung cancer with significant weight loss and anorexia.
A maximum BSA of 2 m2 is commonly used for dose calculations in obese patients. This capping is based in part on small trials which indicate reduced clearance of some chemotherapy agents in obese patients
This study provides a reliable estimate for the mean BSA of men and women receiving chemotherapy in the UK (1.91 and 1.71 respectively). While a tumour specific estimate may be more accurate for some tumour types, these differences were relatively small. This information will not only be of value to those calculating the future cost impact of new chemotherapy agents for which the dose is calculated from the BSA, but also to those estimating the cost-effectiveness of new and established agents.
(0.05 MB XLS)
(0.03 MB DOC)
Body surface area raw data.
(0.58 MB XLS)
We would like to thank Sian Evans and Lyn Jackson, Chief Pharmacists at Velindre Cancer Centre and Dorset Cancer Centre respectively for their involvement in case identification and data collection. Particular thanks also to Dr Helen Wong (Statistician and Clinical Effectiveness Co-ordinator, Clatterbridge Centre for Oncology) for her invaluable assistance.